Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P61328
UPID:
FGF12_HUMAN
Alternative names:
Fibroblast growth factor homologous factor 1; Myocyte-activating factor
Alternative UPACC:
P61328; B2R6B7; B2R976; O35339; P70376; Q8TBG5; Q92912; Q93001
Background:
Fibroblast growth factor 12 (FGF12), also known as Fibroblast growth factor homologous factor 1 and Myocyte-activating factor, plays a pivotal role in nervous system development and function. It is crucial in the positive regulation of voltage-gated sodium channel activity, specifically enhancing the voltage dependence of neuronal sodium channel SCN8A fast inactivation, thereby promoting neuronal excitability.
Therapeutic significance:
FGF12's involvement in Developmental and epileptic encephalopathy 47, a severe early-onset epilepsy with neurodevelopmental impairment, underscores its potential as a therapeutic target. Understanding the role of FGF12 could open doors to potential therapeutic strategies for managing this challenging condition.